|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| Current Assets | ||||||||||
| Cash | ||||||||||
| Accounts receivable | ||||||||||
| Prepaid income tax | ||||||||||
| Prepaid franchise tax | ||||||||||
| Prepaid expenses | ||||||||||
| Total Current Assets | ||||||||||
| Cash and Marketable Securities held in trust account | ||||||||||
| Total Assets | ||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||
| Current liabilities | ||||||||||
| Accounts payable | ||||||||||
| Accrued expenses | ||||||||||
| Income tax payable | ||||||||||
| Franchise tax payable | ||||||||||
| Working capital loan | ||||||||||
| Extension loan | ||||||||||
| Promissory note – related party | ||||||||||
| Excise tax liability | ||||||||||
| Total Current Liabilities | ||||||||||
| Deferred underwriter commission | ||||||||||
| Total Liabilities | ||||||||||
| Class A common stock subject to possible redemption; 1,112,657 shares (at $11.27 per share) at March 31, 2024 and ($11.06 per share) at December 31, 2023 | ||||||||||
| Stockholders’ Deficit | ||||||||||
| Common stock | ||||||||||
| Common Class A | ||||||||||
| Common Class B | ||||||||||
| Total common stock | ||||||||||
| Accumulated deficit | ||||||||||
| Total Stockholders’ Deficit | ||||||||||
| Total Liabilities and Stockholders’ Deficit |
Loading...
